Document and Entity Information
Document and Entity Information | 12 Months Ended |
Dec. 31, 2020shares | |
Cover [Abstract] | |
Entity Registrant Name | Ehave, Inc. |
Entity Central Index Key | 0001653606 |
Document Type | 20-F/A |
Document Period End Date | Dec. 31, 2020 |
Amendment Flag | true |
Amendment Description | The purpose of this Amendment No. 1 (this "Amendment") to our Annual Report on Form 20-F for the period ended December 31, 2020 (the "Form 20-F"), as filed with the Securities and Exchange Commission (the "SEC") on May 28, 2021, is solely to furnish Exhibit 101 to the Form 20-F in accordance with Rule 405 of Regulation S-T. Exhibit 101 to this report provides the consolidated financial statements and related notes from the Form 20-F formatted in XBRL (eXtensible Business Reporting Language). |
Current Fiscal Year End Date | --12-31 |
Entity Well-known Seasoned Issuer | No |
Entity Voluntary Filer | No |
Entity's Current Reporting Status | Yes |
Entity Interactive Data Current | Yes |
Entity Filer Category | Non-accelerated Filer |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
ICFR Auditor Attestation Flag | false |
Entity Shell Company | false |
Entity Common Stock, Shares Outstanding | 67,169,962 |
Document Fiscal Period Focus | FY |
Document Fiscal Year Focus | 2020 |
Document Annual Report | true |
Document Transition Report | false |
Document Shell Company Report | false |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Dec. 31, 2020 | Dec. 31, 2019 |
CURRENT ASSETS: | ||
Cash | $ 1,865,110 | $ 17,530 |
Prepaid expenses | 24,247 | 7,804 |
Refundable taxes | 30,831 | |
Investments | 26,250 | |
Other current assets | 40,000 | |
Total current assets | 1,955,607 | 56,165 |
Other receivables | 440,572 | |
TOTAL ASSETS | 1,955,607 | 496,737 |
CURRENT LIABILITIES: | ||
Accounts payable | 382,225 | 521,432 |
Taxes payables | 6,613 | 6,541 |
Other payables | 2,751,326 | 281,527 |
Advances from former officers and directors | 30,736 | 30,400 |
Promissory notes | 349,079 | 270,018 |
Current portion of convertible notes, net of debt discount of $200,313 | 222,493 | 142,352 |
Derivative liability | 1,250,584 | |
Accrued interest on promissory notes and convertible notes | 53,929 | 51,075 |
Total current liabilities | 3,796,401 | 2,553,929 |
Long-term portion of convertible notes, net of debt discount of $1,310,921 | 432,578 | |
Development grant | 173,583 | |
TOTAL LIABILITIES | 4,228,979 | 2,727,512 |
COMMITMENTS AND CONTINGENCIES | ||
STOCKHOLDERS' DEFICIT: | ||
Common stock, no par value, unlimited shares authorized, 67,169,962 and 25,413,920 issued and outstanding as of December 31, 2020 and 2019, respectively | 7,948,416 | 7,503,984 |
Additional paid in capital | 9,379,990 | 6,338,430 |
Accumulated deficit | (19,729,562) | (16,214,826) |
Accumulated other comprehensive income | 127,784 | 141,637 |
TOTAL STOCKHOLDERS' DEFICIT | (2,273,372) | (2,230,775) |
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ 1,955,607 | $ 496,737 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Statement of Financial Position [Abstract] | ||
Debt discount current | $ 200,313 | $ 200,313 |
Debt discount non current | $ 1,310,921 | |
Common stock, no par value | ||
Common stock, shares authorized | Unlimited | Unlimited |
Common stock, shares issued | 67,169,962 | 25,413,920 |
Common stock, shares outstanding | 67,169,962 | 25,413,920 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Other Comprehensive Income - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Operating expenses | ||
General and administrative | $ 2,046,573 | $ 411,019 |
Total operating expenses | 2,046,573 | 411,019 |
OPERATING LOSS | (2,046,573) | (411,019) |
Other income (expenses) | ||
Interest expense | (2,016,324) | (172,334) |
Amortization expense | (804,356) | |
Change in fair value of derivative liability | (3,004,387) | |
Change in fair value of warrant liability | ||
Gain on settlement of debt | 4,179,971 | |
Other income | 176,933 | |
Foreign exchange (gain) loss | (1,099) | |
Net income (loss) from continuing operations | (3,514,736) | (584,452) |
Loss from discontinued operations | (3,701,024) | |
Gain on sale of intangible assets, net | 648,108 | |
Net loss from discontinued operations | (3,052,916) | |
Net income (loss) | (3,514,736) | (3,637,368) |
Other comprehensive (loss) income | ||
Foreign exchange translation adjustment | (13,853) | (157,541) |
Total other comprehensive income | (13,853) | (157,541) |
Comprehensive income (loss) | (3,528,589) | (3,794,909) |
AMOUNTS ATTRIBUTABLE TO COMMON STOCKHOLDERS | ||
Loss from continuing operations | (3,528,589) | (741,993) |
Loss from discontinued operations | (3,052,916) | |
COMPREHENSIVE NET LOSS | $ (3,528,589) | $ (3,794,909) |
Basic | $ (0.11) | $ (0.03) |
Diluted | (0.11) | (0.03) |
Basic | (0.14) | |
Diluted | (0.14) | |
NET INCOME (LOSS) PER SHARE: | ||
Basic | (0.11) | (0.18) |
Diluted | $ (0.11) | $ (0.18) |
WEIGHTED AVERAGE SHARES OUTSTANDING: | ||
Basic | 32,622,248 | 21,454,189 |
Diluted | 32,622,248 | 21,454,189 |
Consolidated Statement of Chang
Consolidated Statement of Changes in Stockholders' Deficit - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Accumulated (Deficit) [Member] | Accumulated Other Comprehensive Income [Member] | Total |
Beginning balance at Dec. 31, 2018 | $ 1,544,904 | $ 6,999,942 | $ (12,577,458) | $ 299,178 | $ (3,733,434) |
Beginning balance, shares at Dec. 31, 2018 | 751,108 | ||||
Stock based compensation | $ 2,131,920 | 19,871 | 2,151,791 | ||
Stock based compensation, shares | 4,263,840 | ||||
Stock issued in exchange for vested options | $ 681,383 | (681,383) | |||
Stock issued in exchange for vested options, shares | 48,399 | ||||
Share issuance upon Exchange Agreement | $ 3,145,777 | $ 3,145,777 | |||
Share issuance upon Exchange Agreement, shares | 20,350,573 | ||||
Foreign exchange translation | (157,541) | (157,541) | |||
Net Income Loss | (3,637,368) | (3,637,368) | |||
Ending balance at Dec. 31, 2019 | $ 7,503,984 | 6,338,430 | (16,214,826) | 141,637 | (2,230,775) |
Ending balance, shares at Dec. 31, 2019 | 25,413,920 | ||||
Stock based compensation | 928,795 | 928,795 | |||
Stock based compensation, shares | 2,433,357 | ||||
Fair value of warrants issued in connection with convertible debt | 1,412,539 | 1,412,539 | |||
Fair value of beneficial conversion feature issued in connection with convertible debt | 700,226 | 700,226 | |||
Common stock issued upon conversion of debt | $ 378,182 | 378,182 | |||
Common stock issued upon conversion of debt, shares | 37,818,154 | ||||
Common stock issued for CureDash | $ 40,000 | 40,000 | |||
Common stock issued for CureDash, shares | 353,622 | ||||
Common stock issued for Psytech | $ 26,250 | 26,250 | |||
Common stock issued for Psytech,shares | 1,050,000 | ||||
Common stock issued upon cashless warrant exercise | |||||
Common stock issued upon cashless warrant exercise, shares | 100,909 | ||||
Foreign exchange translation | (13,853) | (13,853) | |||
Net Income Loss | (3,514,736) | (3,514,736) | |||
Ending balance at Dec. 31, 2020 | $ 7,948,416 | $ 9,379,990 | $ (19,729,562) | $ 127,784 | $ (2,273,372) |
Ending balance, shares at Dec. 31, 2020 | 67,169,962 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net income (loss) | $ (3,514,736) | $ (3,637,368) |
Loss from discontinued operations | 3,052,916 | |
Loss from continuing operations | (3,514,736) | (584,452) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Stock based compensation | 928,795 | |
Amortization of debt discount | 896,348 | |
Non-cash interest expense | 1,874,963 | |
Gain on settlement of debt | (4,179,971) | |
Gain on forgiveness of development grant | (176,933) | |
Change in fair value of derivative liability | 3,004,387 | |
Change in fair value of warrant liability | ||
Changes in operating assets and liabilities: | ||
Other receivables | 438,579 | (1,314) |
Prepaid expenses and other assets | (16,729) | (7,804) |
Accounts payable and other payables | 677,531 | (80,062) |
Accrued interest on convertible notes | 45 | 111,994 |
Refundable taxes receivable | 29,701 | (21,077) |
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES - CONTINUING OPERATIONS | (38,021) | (582,715) |
NET CASH USED IN OPERATING ACTIVITIES - DISCONTINUED OPERATIONS | (298,649) | |
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES | (38,021) | (881,363) |
NET CASH PROVIDED BY INVESTING ACTIVITIES: | ||
NET CASH PROVIDED BY INVESTING ACTIVITIES - CONTINUING OPERATIONS | 648,108 | |
NET CASH PROVIDED BY INVESTING ACTIVITIES - DISCONTINUED OPERATIONS | ||
NET CASH PROVIDED BY INVESTING ACTIVITIES | 648,108 | |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Proceeds from convertible notes | 2,238,170 | 545,018 |
Repayment of convertible notes | (141,000) | |
Financing fees | (63,500) | |
Repayment of promissory notes | (138,561) | (275,000) |
NET CASH PROVIDED BY FINANCING ACTIVITIES - CONTINUING OPERATIONS | 1,895,109 | 270,018 |
NET CASH PROVIDED BY FINANCING ACTIVITIES -DISCONTINUED OPERATIONS | ||
NET CASH PROVIDED BY FINANCING ACTIVITIES | 1,895,109 | 270,018 |
Effect of exchange rate on cash | (9,508) | (30,455) |
Net increase in cash | 1,847,580 | 6,308 |
Cash, beginning of period | 17,530 | 11,222 |
Cash, end of period | 1,865,110 | 17,530 |
SUPPLEMENTAL CASH FLOW INFORMATION: | ||
Common stock issued for conversion of debt | 378,182 | |
Common stock issued for CureDash | 40,000 | |
Common stock issued for Psytech | 26,250 | |
Accrued interest converted to common stock | 300,362 | |
Debt converted to common stock | $ 2,845,414 |
Organization and Summary of Sig
Organization and Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Organization and Summary of Significant Accounting Policies | 1. ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization and General Description of Business EHAVE, Inc. (formerly known as “Behavioural Neurological Applications and Solutions or 2304101 Ontario Inc.”) (“We” or “the Company”), was incorporated under the laws of the Province of Ontario, Canada on October 31, 2011. The Company is a publicly listed company whose shares are quoted on the Pink Open Market under the symbol EHVVF in the United States. On April 30, 2019, our common shares were removed from the OTCQB Venture Market to the Pink Open Market because we were unable able to cure our bid price deficiency. The Company is a healthcare company developing a health data platform that integrates with proprietary and third-party assessment and therapeutic digital applications. Our product focus is based on two tiers of activities: (1) MegaTeam and Ninja Reflex, our clinically validated digital assessment and rehabilitation software that is engaging for the patient, (2) adaptation of third-party clinically validated digital assessment and rehabilitation software for enhanced patient engagement and data modeling. We intend to provide technology solutions to clinicians, patients, researchers, pharmaceutical companies and payors. The COVID-19 outbreak, which surfaced in Wuhan, China in December 2019 and which was subsequently declared a pandemic by the World Health Organization in March 2020, has had a pronounced effect on the domestic and global economies. The Company’s business has been materially adversely impacted by the recent COVID-19 outbreak and may continue to be materially adversely impacted in the future. The extent of the impact of COVID-19 on the Company’s business, financial results, liquidity and cash flows will depend largely on future developments, including new information that may emerge concerning the severity and action taken to contain or prevent further spread within the U.S. and the related impact on consumer confidence and spending, all of which are highly uncertain and cannot be predicted. Basis of Presentation and principles of consolidation These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. The Company’s functional currency is Canadian dollars. The Company’s fiscal year-end is December 31. The consolidated financial statements include the amounts of the Company and its wholly owned subsidiary, Mycotopia Therapies, Inc. All inter-company accounts and transaction have been eliminated in consolidation. Certain reclassifications have been made to the prior period condensed consolidated financial statements to conform to the current period presentation. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as the Company does not have more than $1,070,000,000 in annual gross revenue and did not have such amount as of December 31, 2020, its last fiscal year. The Company has elected to take advantage of the extended transition period provided in Section 102(b)(1) of the JOBS Act for complying with new or revised accounting standards. Foreign Currency Translation The functional currency of the Company’s foreign operations is generally the local currency of the country in which the operation is located. All assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Revenue and expenses are translated using average exchange rates during the period. The result from currency translation is reflected in stockholders’ deficit as a component of accumulated other comprehensive income. Foreign Currency Risk The Company is exposed to fluctuations in the exchange rate between the United States dollar and the Canadian dollar. The Company’s continued financing activities are primarily in United States dollars while the Company’s expenditures are primarily in Canadian dollars. Should the exchange rate between the Canadian dollar and the United States dollar fluctuate, the Company may be exposed to resource constraints. Software Products and Research and Development Software development costs are expensed as incurred and consist primarily of design and development costs of new products, and significant enhancements to existing products incurred before the establishment of technological feasibility. Costs incurred subsequent to technological feasibility of new and enhanced products, costs incurred to purchase or to create and implement internal-use software, and software obtained through business acquisitions are capitalized. Such costs are amortized over the estimated useful lives of the related products, using the straight-line method. Income Taxes Income tax expense is based on income before income taxes and is accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are recorded when it is more likely than not that a deferred tax asset will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Considerable judgment is required in assessing and estimating these amounts and the difference between the actual outcome of these future tax consequences and the estimates made could have a material impact on the operating results. To the extent that new information becomes available which causes the Company to change its judgment regarding the adequacy of existing tax liabilities, such changes to tax liabilities will impact income tax expense in the period in which such determination is made. The Company records interest and penalties related to unrecognized tax benefits in income tax expense. The Company has made applications for Ontario Interactive Digital Media Tax Credits (“OIDMTC”). Judgment is required in the determination of qualifying expenses. The final determination of qualifying expenses is not known until acceptance by tax authorities. The Company’s credits have been reflected in the financial statements. (See Note. 5 “Other Receivable”) Net Loss per Common Share, basic The Company has adopted Accounting Standards Codification (“ASC”) subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share (EPS) information. Basic earnings (loss) per share includes no dilution and is computed by dividing net income or loss by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution of securities that could share in the earnings or losses of the entity. At December 31, 2020, the Company had outstanding warrants to purchase 28,693,368 common shares and 216,630,546 common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive. Recent Pronouncements During the years ended December 31, 2020 and 2019 there were several new accounting pronouncements issued by the Financial Accounting Standards Board (FASB). Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements. |
Going Concern
Going Concern | 12 Months Ended |
Dec. 31, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Going Concern | 2. GOING CONCERN The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States, which contemplate the continuation of the Company as a going concern. Through December 31, 2020, the Company has incurred an accumulated deficit of $19,729,562, primarily as a result of expenses incurred through a combination of development and commercialization activities related to our products and general and administrative expenses supporting those activities, as well as an operating loss of $3,514,736. Our total cash balance as of December 31, 2020 was $1,865,110. At December 31, 2020, we had a working capital deficit of $1,840,794. We anticipate that we will continue to incur losses and negative cash flows from operations, and that such losses will increase over the next several years. As a result of these expected losses and negative cash flows from operations, along with our current cash position, we may not have sufficient resources to fund operations for one year from the date we issued these financial statements. Therefore, there is substantial doubt about our ability to continue as a going concern. |
Fair Value Measurement
Fair Value Measurement | 12 Months Ended |
Dec. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurement | 3. FAIR VALUE MEASUREMENT ASC Topic 820, Fair Value Measurement |
Sale of Intangible Assets and D
Sale of Intangible Assets and Discontinued Operation | 12 Months Ended |
Dec. 31, 2020 | |
Sale Of Intangible Assets And Discontinued Operation | |
Sale of Intangible Assets and Discontinued Operation | 4. SALE OF INTANGIBLE ASSETS AND DISCONTINUED OPERATION On March 22, 2019 the Company entered into an asset purchase agreement with Zyus Life Sciences, Inc. (“Zyus”) and completed the sales of certain intellectual property assets and rights relating to the Company’s health informatics platform (the “Asset Purchase Agreement”). In accordance with the Asset Purchase Agreement, the Company received in the aggregate from Zyus (i) CAD $1.2 million in cash, and (ii) 361,011 of Zyus common shares. During the year ended December 31, 2019, the Company recorded CAD $551,892 of expenses directly associated with the Asset Purchase Agreement and recorded a gain on the sale of intangible assets, net, in the amount of $648,108. There is no value recorded for the Zyus common shares due to the lack of an active market and ascertainable value. With the consummation of this sale, the Company’s current operations were discontinued due to the elimination of the ongoing operations and cash flows of the component, the resignation of then current executive management and abandonment of its leased facilities. Operating results for the years ended December 31, 2019 for the Ehave Connect platform and related operating expenses are presented as discontinued operations as follows: Year Ended December 31, 2019 Operating expenses from discontinued operation General and administrative expenses $ 2,450,440 Total operating expenses from discontinued operation 2,450,440 OPERATING LOSS FROM DISCONTINUED OPERATION (2,450,440 ) Change in fair market value of derivative liabilities (1,250,584 ) Gain on sale of intangible assets, net 648,108 Net loss from discontinued operations $ (3,052,916 ) |
Other Receivable
Other Receivable | 12 Months Ended |
Dec. 31, 2020 | |
Other Receivable | |
Other Receivable | 5. OTHER RECEIVABLE As of December 31, 2019, other receivables includes $300,018 that relates to filed applications for Ontario Interactive Media Tax Credits. The Company recently filed an amended 2016 tax return and its 2018 tax return in order to receive payment for the Ontario Interactive Media Tax Credits. The review process has been completed and the Canada Revenue Agency issued the refund in full. |
Related Party Transactions
Related Party Transactions | 12 Months Ended |
Dec. 31, 2020 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 6. RELATED PARTY TRANSACTIONS The related party transactions are as follows: During the year ended December 31, 2020, the Company issued two convertible promissory notes to a related party for the principal amount of $256,520, in the aggregate, including $23,320 of original issue discount and 2,565,200 warrants, in the aggregate, with an exercise price of $0.01 per share. The term of the notes is 18 months and carries an effective interest rate of 8.00%. $178,189 of the note matures on July 17, 2021 and $78,331 matures on July 29, 2021. The convertible promissory note is convertible into shares of common stock at $0.01 per share. During the year ended December 31, 2020, the Company issued a convertible promissory note to a related party for the principal amount of $11,000, in the aggregate, including $1,000 of original issue discount and 110,000 warrants, in the aggregate, with an exercise price of $0.01 per share. The term of the note is 18 months and carries an effective interest rate of 8.00%. The note matures on May 11, 2022. On August 4, 2020, the Company issued 775,194 shares of common stock, in the aggregate, to two individuals who are a related party and directors of the Company for services rendered. On April 18, 2019, the Company terminated the agreement it entered into CHT on October 30, 2018 (the “CHT Agreement”) regarding the exclusive rights to Ehave Connect granted to CHT for use in companion animals. Pursuant to the agreement to terminate the CHT Agreement, the Company paid CHT, in cash, CAD $230,170, which includes CAD $25,170 for legal fees that CHT incurred in connection with the CHT Agreement, from the proceeds of the Asset Sale. On January 28, 2019, the Company issued demand non-interest bearing senior secured promissory notes in the aggregate principal amount of $85,756 (CAD$125,000), including $18,841(CAD$25,000) of original issue discount. Binyomin Posen and Zeke Kaplan, directors of the Company, have personal and business relations with some of the lenders. The principal amount of $85,756 was repaid on May 24, 2019. On February 27, 2019, the Company issued 1,268,378 common shares of the Company valued at $634,189 in exchange for services performed by multiple parties, one of which is a significant shareholder. Binyomin Posen and Zeke Kaplan, directors of the Company, have personal and business relations with one of the vendors who exchanged fees. On February 27, 2019, we entered into an exchange agreement (the “Exchange Agreement”) with a significant shareholder to convert the 2018 unsecured debentures, secured debentures, and senior secured promissory notes (the “2018 Converted Debt”) into common stock. Under the terms of the Exchange Agreement, the Company issued in the aggregate 20,350,573 shares of common stock upon the conversion of, in the aggregate, $3,145,777 of outstanding principal and interest and the cancellation of 560,461 warrants related to the 2018 Converted Debt. On September 24, 2018, the Company entered into a letter agreement (the “Letter Agreement”) in which the Company and Scott Woodrow, a related party and former Director of the Company, agreed to convert the outstanding convertible debentures and cancel the outstanding warrants. On February 27, 2019, the Company granted 475,642 shares of common stock to Scott Woodrow in connection with the letter agreements. On March 26, 2019, the Company issued demand non-interest bearing senior secured promissory notes in the aggregate principal amount of $98,351 (CAD$131,683), including $23,663 (CAD$31,683) of original issue discount. Binyomin Posen and Zeke Kaplan, directors of the Company, have personal and business relations with some of the lenders. The principal amount of $95,351 was repaid on May 24, 2019. On June 24, 2019, the Company entered into an Executive Consulting Agreement with Benjamin Kaplan to serve as the Company’s CEO for an initial term of 24 months. As of December 31, 2020 and 2019, the Company has accrued $2,194,963 and $172,091, respectively, as other payables in relation to the Executive Consulting Agreement. Of the $2,194,963, $1,874,963 was recorded as interest expense during the year ending December 31, 2020 related to 15,624,694 shares of common stock owed in relation to capital raises. During the year ending December 31, 2020, the Company has recorded $1,040,694 as general and administrative expense related to compensation of which $720,964 is recorded as stock based compensation. During the year ending December 31, 2019, the Company recorded $172,091 as general and administrative expense related to the Executive Consulting Agreement. |
Promissory and Convertible Note
Promissory and Convertible Notes | 12 Months Ended |
Dec. 31, 2020 | |
Debt Disclosure [Abstract] | |
Promissory and Convertible Notes | 7. PROMISSORY AND CONVERTIBLE NOTES During the year ended December 31, 2020, the Company issued convertible promissory notes in the principal amount of $2,544,487, in the aggregate, and including $267,520 issued to related parties. The principal amount includes $231,317 of original issue discount and 2,544,870 warrants with an exercise price of $0.01 per share. The term of the notes are 18 months and carry an effective interest rate of 8.00%. The notes mature beginning on July 10, 2021 thru June 28, 2022. The convertible promissory notes are convertible into shares of common stock at $0.01 per share. The Company recorded a debt discount in the amount of $2,407,582, in the aggregate, in relation to the original issue discount, conversion feature and warrants. During the year ended December 31, 2020, the Company converted $378,182 of principal debt and issued 37,818,154 shares of common stock, in the aggregate, upon conversion of the convertible promissory notes. During the year ended December 31, 2020, the Company recorded amortization expense in the amount of $896,348 in relation to the amortization of debt discount of which $804,356 was recorded as amortization expense in relation to the warrants and conversion feature and $91,992 was recorded as interest expense in relation to the original issue discount and financing fees in the consolidated statements of operations and comprehensive income. On January 21, 2019, we issued a senior secured promissory note in the aggregate principal amount of $263,192 (CAD$350,000). The secured promissory note is secured against certain of our assets, including all development tax credits that the Company has applied for and receives. During the year ending December 31, 2020, the Company repaid the note in full. On January 28, 2019, we issued demand non-interest bearing senior secured promissory notes in the aggregate principal amount of $85,756 (CAD$125,000), including $18,841(CAD$25,000) of original issue discount. The principal amount of $85,756 was repaid on May 24, 2019. Exchange Agreement On February 27, 2019, we entered into Exchange Agreement with a significant shareholder to convert the 2018 Converted Debt into common stock. Under the terms of the Exchange Agreement, the Company issued in the aggregate 20,350,573 shares of common stock upon the conversion of, in the aggregate, $3,145,777 of outstanding principal and interest and the cancellation of 560,461 warrants related to the 2018 Converted Debt (see Note 6). |
Development Grant
Development Grant | 12 Months Ended |
Dec. 31, 2020 | |
Development Grant | |
Development Grant | 8. DEVELOPMENT GRANT On June 7, 2012, the Company entered into a project funding agreement with the Canada-Israel Research and Development Foundation (“CIIRDF”). The purpose of the grant was to fund the Company’s activities related to the development of a cognitive assessment and treatment platform for childhood attention deficit disorder and attention hyperactivity disorder (the “Development”). Under the terms of the grant, CIIRDF would fund up to CAD$300,000 of development activities related to the Development. The grant is repayable to CIIRDF based on 2.5% of annual gross sales related to products developed from the Development. The Company received CAD$225,000 from CIIRDF to fund the Development. The Company no longer pursues the Development, and the grant is no longer payable as no sales will be generated from the Development. During the year ending December 31, 2020, the Company recorded $176,933 as other income in relation to the grant. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 9. INCOME TAXES The Company computes income taxes using the asset and liability approach. The Company currently has no issue that creates timing differences that would mandate a deferred tax expense. Due to the uncertainty as to the utilization of net operating loss carryforwards, a valuation allowance has been made to the extent of any tax benefit that net operating losses may generate. No provision for income tax has been recorded for the years ended December 31, 2020 and December 31, 2019 due to the Company’s operating losses. The Company previously filed applications for Ontario Interactive Digital Media Tax Credits (the “Tax Credits”). During the year ending December 31, 2020, the Company was refunded the Tax Credits in full. As of December 31, 2020 and 2019, the Company has a net operating loss for tax purposes of CAD $8,603,671 and CAD $6,143,402, respectively, that can be carried forward over 20 years. Deferred Income Taxes Deferred income taxes primarily represent the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. The components of the Company’s deferred taxes are as follows: 2020 2019 Deferred tax assets (liabilities): Deferred tax asset, beginning $ 741,000 $ 704,000 Increase in valuation reserve 333,000 37,000 Deferred tax asset, ending 1,074,000 741,000 Valuation Allowance (1,074,000 ) (741,000 ) Net Deferred tax assets $ - $ - |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 10. COMMITMENTS AND CONTINGENCIES Collaboration Agreement The Company entered into a collaboration agreement with a hospital located in Canada. As of December 31, 2020 and 2019, a the Company recorded $10,000 and $5,000, respectively, for the annual royalty due under the terms of the collaboration agreement. Consulting Agreement On June 24, 2019, the Company entered into an Executive Consulting Agreement (Agreement) with Benjamin Kaplan (BK) to serve as the Company’s CEO for an initial term of 24 months. In addition to the monthly consulting fee, the Agreement provides for a one month ‘termination fee’ if the Agreement is terminated without cause. On June 29, 2019, the Company and BK amended the Agreement as follows: BK was granted a Warrant to purchase that number of shares of common stock of the Company equal to 5% of the issued and outstanding common shares, on a fully diluted basis. The Warrant was issued on April 16, 2020, has an exercise price of $0.01 USD per share and shall expire April 16, 2022. Upon the closing of a Significant Transaction (defined as the closing of financing for at least $500,000 or the closing of an acquisition with a valuation (determined by the value of the consideration paid by the Company) of not less than $1,000,000 USD), BK would be granted a number of shares equal to 5% of the issued and outstanding common shares, on a fully diluted basis including such shares to be issued or that could be issued pursuant to the transaction on the closing date of such Significant Transaction. This stock grant can be earned by BK for each Significant Transaction closed during the term of the Agreement. As of December 31, 2020, a Significant Transaction has not consummated. During the year ending December 31, 2020, the Company closed the significant transaction and raised over $500,000. As of December 31, 2020, the Company owes BK 15,624,694 shares of common stock. As of and for the year ended December 31, 2020, the Company recorded $1,874,963 as other payables and interest expense in relation to the shares owed. On January 1, 2020, the Company entered into a consulting agreement for investor relations services. The Company shall pay the consultant $6,500 per month for services rendered to be paid $2,500 in cash and $4,000 in common shares of the Company to be valued at a 20% discount to the lowest trading price for the five trading days prior to date upon which payment is due. As of and during the year ending December 31, 2020, the Company recorded $109,159 as other payables and consulting expense related to this agreement. As of December 31, 2020, the Company owed 876,225 shares of common stock in relation to this agreement. Medical Advisory Board Agreements During the year ended December 31, 2020, the Company entered into medical advisory board agreements with three members for a term of one year each. As consideration for the services to be rendered, the Company agreed to pay $10,000 in cash and $155,000 worth of stock in common stock. During the year ended December 31, 2020, the Company recorded $105,438 as general and administrative expense in accordance with the agreements. As of December 31, 2020, the Company accrued $105,438 as other payables in accordance with these agreements. Leases The Company currently reimburses an entity owned by its CEO for office space and related expenses that he has under lease. The lease expense is $2,500 per month. The Company does not own or lease any other office space, manufacturing facilities or equipment and does not have any current plans to construct or acquire any facilities. During the years ending December 31, 2020 and 2019, the Company expensed approximately $73,000 and $18,000, respectively, for office space and related expenses. As of December 31, 2020 and 2019, the Company accrued approximately $91,000 and $18,000 as other payables for amounts owed to the entity. Novel coronavirus Any serious disruption with the Company’s suppliers or customers due to the COVID-19 outbreak could impair the Company’s ability to meet and/or generate demand for its product, which may negatively impact the Company’s revenue, financial condition, and commercial operations. Such outbreaks could also result in delays in or the suspension of the Company’s research and product development activities, regulatory work streams, its clinical studies and other important functions. The Company is unable to predict the outcome of these matters and is unable to make a meaningful estimate of the amount or range of loss, if any, that could result from an unfavorable outcome. |
Stockholders' Equity (Deficit)
Stockholders' Equity (Deficit) | 12 Months Ended |
Dec. 31, 2020 | |
Equity [Abstract] | |
Stockholders' Equity (Deficit) | 11. STOCKHOLDERS’ EQUITY (DEFICIT) On September 15, 2020, the Company issued 1,050,000 shares of common stock in accordance with a strategic alliance agreement and as consideration for the purchase of 1,050,000 share of Psychedelitech, Inc. (“Psychedelitech”) (a private Ontario corporation). As a result of the transaction, the Company purchased 10% of Psychedelitech. The shares were recorded at fair market value on the date of issuance of $26,250. As of December 31, 2020, the investment in Psychedelitech is recorded at cost in the amount of $26,250. During the year ended December 31, 2020, the Company issued 37,818,154 shares of common stock, in the aggregate, upon conversion of the convertible promissory notes (see Note 7). During the year ended December 31, 2020, the Company issued 100,909 shares of common stock upon the cashless exercise of 110,000 warrants. On December 31, 2020, the Company issued 353,622 shares of common stock in relation to an asset sale and purchase agreement entered into on January 21, 2021 (see “Subsequent Events”). The shares were recorded at fair market value on the date of issuance of $40,000. As of December 31, 2020, the Company recorded this amount as other current asset in the consolidated balance sheet. On February 27, 2019, the Company converted $2,845,414 (CAD $3,740,431), the net carrying value of the principal balance of convertible notes payable and promissory notes payable, and $300,362 (CAD $394,693) of accrued interest into 19,711,362 shares of common stock pursuant to letter agreements with the holders of existing notes and warrants. STOCK BASED COMPENSATION During the year ended December 31, 2020, the Company entered into a finder’s fee agreement with a consultant to assist the Company in procuring sources of financing such as equity, debt, or a merger or sale of the Company. Total compensation for the consultant’s efforts and services shall be a cash fee of 10% of the total principal amount of gross proceeds from any financing and 10% of the total shares of common stock purchased or convertible equivalent. During the year ending December 31, 2020, the Company issued 1,250,000 shares of common stock which was recorded at fair value of $46,875 and paid $63,500 in relation to the finder’s fee agreement. The Company recognized these amounts as interest expense in the Company’s consolidated statements of operations and other comprehensive loss during the year ended December 31, 2020. During the year ended December 31, 2020, the Company issued 3,358,498 vested warrants to Ben Kaplan, the Company’s CEO, in accordance with his employment agreement valued at $720,695. The Company expensed $720,695 as general and administrative expense in relation to this issuance. The Company valued these warrants using the Black-Scholes option pricing model using the following assumptions: a) stock prices of $0.37 and $0.12, b) exercise price of $0.01, c) dividend rate of 0%, d) risk free rates of 0.20% and 0.13%, and e) expected volatility of 570% and 648%. On August 1, 2020, the Company issued 408,163 shares of common stock to a consultant for services rendered. The Company expensed $61,224 in relation to this issuance. On August 4, 2020, the Company issued 387,597 shares of common stock to a member of management for services rendered. The Company expensed $50,000 in relation to this issuance. On August 4, 2020, the Company issued 387,597 shares of common stock to a related party for services rendered. The Company expensed $50,000 in relation to this issuance. On February 27, 2019, the Company granted 475,642 shares of common stock to Scott Woodrow, a related party and former Director of the Company, in connection with letter agreements (see Note 6). On February 27, 2019, the Company issued 317,095 shares of common stock in exchange for services fair valued at $158,547 to KW Capital Partners Ltd. On February 27, 2019, the Company issued 475,642 shares of common stock in exchange for services fair valued at $237,821 to Bezalel Partners LLC. On February 27, 2019, the Company entered into an agreement to cancel 2,250,000 compensation warrants that had anti-rachet and anti-dilution provisions for 328,111 common shares of the Company. A Summary of the status of the Company’s option grants as of December 31, 2020 and 2019 and the changes during the periods then ended is presented below: Shares Weighted- Weighted Aggregate Outstanding January 1, 2019 86,251 $ - 5.0 $ - Granted - - - - Exercised - - - - Canceled (86,251 ) - - - Outstanding December 31, 2019 - - - - Granted - - - - Exercised - - - - Canceled - - - - Outstanding December 31, 2020 - $ - - $ - Warrants Issued The following table reflects a summary of Common Stock warrants outstanding and warrant activity during the year ended December 31, 2020 and 2019 Underlying Weighted Average Exercise Price Weighted Average Term (Years) Warrants outstanding at January 1, 2019 561,461 $ - - Granted - - - Exercised - - - Forfeited 560,461 - - Warrants outstanding at December 31, 2019 - - - Granted 28,803,368 0.01 1.41 Exercised (110,000 ) 0.01 Forfeited - - - Warrants outstanding and exercisable at December 31, 2020 28,693,368 $ 0.01 1.12 The intrinsic value of warrants outstanding as of December 31, 2020 was $2,926,612. The warrants granted during the year ending December 31, 2020 were valued using the Black-Scholes option pricing model using the following weighted average assumptions: Year Ended December 31, 2020 Expected term, in years 2.83 Expected volatility 162.24 % Risk-free interest rate 0.44 % Dividend yield - |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2020 | |
Subsequent Events [Abstract] | |
Subsequent Events | 12. SUBSEQUENT EVENTS Subsequent to December 31, 2020, the Company issued 15,649,446 shares of common stock upon the conversion of $156,494 of convertible notes payable. On January 19, 2021, the Company consummated its agreement with the former and current directors of 20/20 Global, Inc. (“20/20 Global”) that provide for: (i) 20/20 Global’s purchase for $350,000 in cash of all of the outstanding stock of Mycotopioa Therapies, Inc. (“MYC”), the Company’s wholly owned subsidiary, from Ehave under a Stock Purchase Agreement, resulting in MYC becoming a wholly owned subsidiary of 20/20 Global; and (ii) the change of control of 20/20 Global’s board of directors and management. In a related transaction, Ehave agreed to purchase 9,793,754 shares of 20/20 Global common stock, which constitute approximately 75.77% of the issued and outstanding shares of 20/20 Global’s common stock, for $350,000 in cash. On January 19, 2021, the above transaction closed. Because Ehave acquired 75.77% of 20/20 Global outstanding stock and there was a change in control of 20/20 Global’s board of directors, the transaction was accounted for as a reverse merger in which Mycotopia Therapies, Inc. was deemed to be the accounting acquirer and 20/20 Global the legal acquirer. On January 21, 2021, the Company entered into an asset sale and purchase agreement with CureDash, Inc. (a Delaware Corporation) (“CureDash” or the “Seller”). The Company purchased tangible and intangible assets from the Seller in order to begin a new venture in psychosis therapy. The purchase price of the assets is $100,000 payable with the issuance of 353,622 shares of common stock and $60,000 in cash which was paid upon closing on January 21, 2021. Subsequent to year end, the Company received aggregate investments of $1,159,000 and issued 16,557,142 shares of common stock from the Regulation A Offering that was qualified in January 2021. Subsequent to year end, the Company received proceeds of $522,000 from promissory notes. The notes carry an additional original issue discount payable of $52,750 representing interest as no other interest accrues on the notes unless there is an event of default, at which time interest will accrue at 22.0%, The notes mature eighteen months after the dates of issuance. The holder of the notes can exercise conversion at any time the note remains outstanding at a price of $0.01 per share. Upon the closing of a financing event of the Company, the notes will automatically convert at the conversion price of $0.01 per share. Attached to the notes is a warrant to purchase common stock entitling the holder to purchase up to a number of shares equal to ten times the face amount of the note at an exercise price of $0.01 per share. The warrant expires two years from the date of issuance. Subsequent to year end, the Company issued 1,746,084 shares of common stock upon the cashless exercise of 1,870,000 warrants. Subsequent to year end, the Company issued 281,000 shares of common stock is accordance with a medical advisory board agreement. |
Organization and Summary of S_2
Organization and Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Organization and General Description of Business | Organization and General Description of Business EHAVE, Inc. (formerly known as “Behavioural Neurological Applications and Solutions or 2304101 Ontario Inc.”) (“We” or “the Company”), was incorporated under the laws of the Province of Ontario, Canada on October 31, 2011. The Company is a publicly listed company whose shares are quoted on the Pink Open Market under the symbol EHVVF in the United States. On April 30, 2019, our common shares were removed from the OTCQB Venture Market to the Pink Open Market because we were unable able to cure our bid price deficiency. The Company is a healthcare company developing a health data platform that integrates with proprietary and third-party assessment and therapeutic digital applications. Our product focus is based on two tiers of activities: (1) MegaTeam and Ninja Reflex, our clinically validated digital assessment and rehabilitation software that is engaging for the patient, (2) adaptation of third-party clinically validated digital assessment and rehabilitation software for enhanced patient engagement and data modeling. We intend to provide technology solutions to clinicians, patients, researchers, pharmaceutical companies and payors. The COVID-19 outbreak, which surfaced in Wuhan, China in December 2019 and which was subsequently declared a pandemic by the World Health Organization in March 2020, has had a pronounced effect on the domestic and global economies. The Company’s business has been materially adversely impacted by the recent COVID-19 outbreak and may continue to be materially adversely impacted in the future. The extent of the impact of COVID-19 on the Company’s business, financial results, liquidity and cash flows will depend largely on future developments, including new information that may emerge concerning the severity and action taken to contain or prevent further spread within the U.S. and the related impact on consumer confidence and spending, all of which are highly uncertain and cannot be predicted. |
Basis of Presentation and Principles of Consolidation | Basis of Presentation and principles of consolidation These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. The Company’s functional currency is Canadian dollars. The Company’s fiscal year-end is December 31. The consolidated financial statements include the amounts of the Company and its wholly owned subsidiary, Mycotopia Therapies, Inc. All inter-company accounts and transaction have been eliminated in consolidation. Certain reclassifications have been made to the prior period condensed consolidated financial statements to conform to the current period presentation. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as the Company does not have more than $1,070,000,000 in annual gross revenue and did not have such amount as of December 31, 2020, its last fiscal year. The Company has elected to take advantage of the extended transition period provided in Section 102(b)(1) of the JOBS Act for complying with new or revised accounting standards. |
Foreign Currency Translation | Foreign Currency Translation The functional currency of the Company’s foreign operations is generally the local currency of the country in which the operation is located. All assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Revenue and expenses are translated using average exchange rates during the period. The result from currency translation is reflected in stockholders’ deficit as a component of accumulated other comprehensive income. |
Foreign Currency Risk | Foreign Currency Risk The Company is exposed to fluctuations in the exchange rate between the United States dollar and the Canadian dollar. The Company’s continued financing activities are primarily in United States dollars while the Company’s expenditures are primarily in Canadian dollars. Should the exchange rate between the Canadian dollar and the United States dollar fluctuate, the Company may be exposed to resource constraints. |
Software Products and Research and Development | Software Products and Research and Development Software development costs are expensed as incurred and consist primarily of design and development costs of new products, and significant enhancements to existing products incurred before the establishment of technological feasibility. Costs incurred subsequent to technological feasibility of new and enhanced products, costs incurred to purchase or to create and implement internal-use software, and software obtained through business acquisitions are capitalized. Such costs are amortized over the estimated useful lives of the related products, using the straight-line method. |
Income Taxes | Income Taxes Income tax expense is based on income before income taxes and is accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are recorded when it is more likely than not that a deferred tax asset will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Considerable judgment is required in assessing and estimating these amounts and the difference between the actual outcome of these future tax consequences and the estimates made could have a material impact on the operating results. To the extent that new information becomes available which causes the Company to change its judgment regarding the adequacy of existing tax liabilities, such changes to tax liabilities will impact income tax expense in the period in which such determination is made. The Company records interest and penalties related to unrecognized tax benefits in income tax expense. The Company has made applications for Ontario Interactive Digital Media Tax Credits (“OIDMTC”). Judgment is required in the determination of qualifying expenses. The final determination of qualifying expenses is not known until acceptance by tax authorities. The Company’s credits have been reflected in the financial statements. (See Note. 5 “Other Receivable”) |
Net Loss Per Common Share, Basic | Net Loss per Common Share, basic The Company has adopted Accounting Standards Codification (“ASC”) subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share (EPS) information. Basic earnings (loss) per share includes no dilution and is computed by dividing net income or loss by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution of securities that could share in the earnings or losses of the entity. At December 31, 2020, the Company had outstanding warrants to purchase 28,693,368 common shares and 216,630,546 common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive. |
Recent Pronouncements | Recent Pronouncements During the years ended December 31, 2020 and 2019 there were several new accounting pronouncements issued by the Financial Accounting Standards Board (FASB). Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements. |
Sale of Intangible Assets and_2
Sale of Intangible Assets and Discontinued Operation (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Sale Of Intangible Assets And Discontinued Operation - Schedule Of Discontinued Operations Of Operating Expenses | |
Schedule of Discontinued Operations of Operating Expenses | Operating results for the years ended December 31, 2019 for the Ehave Connect platform and related operating expenses are presented as discontinued operations as follows: Year Ended December 31, 2019 Operating expenses from discontinued operation General and administrative expenses $ 2,450,440 Total operating expenses from discontinued operation 2,450,440 OPERATING LOSS FROM DISCONTINUED OPERATION (2,450,440 ) Change in fair market value of derivative liabilities (1,250,584 ) Gain on sale of intangible assets, net 648,108 Net loss from discontinued operations $ (3,052,916 ) |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |
Schedule of Components of Deferred Tax Assets | The components of the Company’s deferred taxes are as follows: 2020 2019 Deferred tax assets (liabilities): Deferred tax asset, beginning $ 741,000 $ 704,000 Increase in valuation reserve 333,000 37,000 Deferred tax asset, ending 1,074,000 741,000 Valuation Allowance (1,074,000 ) (741,000 ) Net Deferred tax assets $ - $ - |
Stockholders' Equity (Deficit)
Stockholders' Equity (Deficit) (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Equity [Abstract] | |
Schedule of Stock Option Activity | A Summary of the status of the Company’s option grants as of December 31, 2020 and 2019 and the changes during the periods then ended is presented below: Shares Weighted- Weighted Aggregate Outstanding January 1, 2019 86,251 $ - 5.0 $ - Granted - - - - Exercised - - - - Canceled (86,251 ) - - - Outstanding December 31, 2019 - - - - Granted - - - - Exercised - - - - Canceled - - - - Outstanding December 31, 2020 - $ - - $ - |
Schedule of Warrants Activity | The following table reflects a summary of Common Stock warrants outstanding and warrant activity during the year ended December 31, 2020 and 2019 Underlying Weighted Average Exercise Price Weighted Average Term (Years) Warrants outstanding at January 1, 2019 561,461 $ - - Granted - - - Exercised - - - Forfeited 560,461 - - Warrants outstanding at December 31, 2019 - - - Granted 28,803,368 0.01 1.41 Exercised (110,000 ) 0.01 Forfeited - - - Warrants outstanding and exercisable at December 31, 2020 28,693,368 $ 0.01 1.12 |
Schedule of Weighted Average Assumptions of Warrants | The warrants granted during the year ending December 31, 2020 were valued using the Black-Scholes option pricing model using the following weighted average assumptions: Year Ended December 31, 2020 Expected term, in years 2.83 Expected volatility 162.24 % Risk-free interest rate 0.44 % Dividend yield - |
Organization and Summary of S_3
Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($) | Feb. 27, 2019 | Dec. 31, 2020 |
Antidilutive Securities excluded from computation of earnings per share, amount | 328,111 | |
Warrants [Member] | ||
Antidilutive Securities excluded from computation of earnings per share, amount | 28,693,368 | |
Common Shares [Member] | ||
Antidilutive Securities excluded from computation of earnings per share, amount | 216,630,546 | |
Minimum [Member] | ||
Emerging growth company, expected minimum gross revenue | $ 1,070,000,000 |
Going Concern (Details Narrativ
Going Concern (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Accumulated deficit | $ (19,729,562) | $ (16,214,826) |
Net loss | (3,514,736) | (3,637,368) |
Cash | 1,865,110 | $ 17,530 |
Working capital deficit | $ 1,840,794 |
Sale of Intangible Assets and_3
Sale of Intangible Assets and Discontinued Operation (Details Narrative) | Mar. 22, 2019CAD ($)shares | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | Dec. 31, 2019CAD ($) |
Gain on sale of intangible assets, net | $ 648,108 | |||
Asset Purchase Agreement [Member] | Zyus Life Sciences, Inc [Member] | ||||
Number of shares acquired on purchase of assets | shares | 361,011 | |||
Asset Purchase Agreement [Member] | Zyus Life Sciences, Inc [Member] | CAD [Member] | ||||
Cash received from agreement | $ 1,200,000 | |||
Expenses related to purchase agreement | $ 551,892 | |||
Gain on sale of intangible assets, net | $ 648,108 |
Sale of Intangible Assets and_4
Sale of Intangible Assets and Discontinued Operation - Schedule of Discontinued Operations of Operating Expenses (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Sale Of Intangible Assets And Discontinued Operation - Schedule Of Discontinued Operations Of Operating Expenses | ||
General and administrative expenses | $ 2,450,440 | |
Total operating expenses from discontinued operation | 2,450,440 | |
OPERATING LOSS FROM DISCONTINUED OPERATION | (2,450,440) | |
Change in fair market value of derivative liabilities | (1,250,584) | |
Gain on sale of intangible assets, net | 648,108 | |
Net loss from discontinued operations | $ (3,052,916) |
Other Receivable (Details Narra
Other Receivable (Details Narrative) | Dec. 31, 2019USD ($) |
Ontario Interactive Media Tax Credits [Member] | |
Other receivables | $ 300,018 |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) | Aug. 04, 2020shares | Aug. 02, 2020shares | May 24, 2020USD ($) | Apr. 18, 2020CAD ($) | Jun. 24, 2019 | May 24, 2019USD ($) | Feb. 27, 2019USD ($)shares | Feb. 27, 2019USD ($)shares | Feb. 27, 2019USD ($)shares | Dec. 31, 2020USD ($)$ / sharesshares | Dec. 31, 2019USD ($) | Jun. 29, 2019$ / shares | Mar. 26, 2019USD ($) | Mar. 26, 2019CAD ($) | Jan. 28, 2019USD ($) | Jan. 28, 2019CAD ($) |
Debt instrument, principal amount | $ 2,845,414 | $ 2,845,414 | $ 2,845,414 | |||||||||||||
Number of shares issued for services, shares | shares | 378,597 | 408,163 | ||||||||||||||
Debt conversion shares issued | shares | 19,711,362 | |||||||||||||||
Cancellation of warrants | shares | 100,909 | |||||||||||||||
General and administrative expenses | $ 2,046,573 | $ 411,019 | ||||||||||||||
Stock based compensation | 928,795 | |||||||||||||||
CAD [Member] | ||||||||||||||||
Debt instrument, principal amount | $ 3,740,431 | $ 3,740,431 | $ 3,740,431 | |||||||||||||
CHT Agreement [Member] | CAD [Member] | Cash Payment [Member] | ||||||||||||||||
Repayments to related party debt | $ 230,170 | |||||||||||||||
CHT Agreement [Member] | CAD [Member] | Legal Fees in Connection with Agreement [Member] | ||||||||||||||||
Repayments to related party debt | $ 25,170 | |||||||||||||||
Executive Consulting Agreement [Member] | ||||||||||||||||
Repayments to related party debt | 2,194,963 | 172,091 | ||||||||||||||
Interest expenses on debt | $ 1,874,963 | |||||||||||||||
Common stock owed | shares | 15,624,694 | |||||||||||||||
General and administrative expenses | $ 1,040,694 | $ 172,091 | ||||||||||||||
Executive Consulting Agreement [Member] | General and Administrative Expense [Member] | ||||||||||||||||
Stock based compensation | $ 720,964 | |||||||||||||||
Directors [Member] | ||||||||||||||||
Number of shares issued for services, shares | shares | 775,194 | |||||||||||||||
Multiple Parties [Member] | ||||||||||||||||
Number of shares issued for services, shares | shares | 634,189 | |||||||||||||||
Number of shares issued for services | $ 1,268,378 | |||||||||||||||
Scott Woodrow [Member] | Exchange Agreement [Member] | ||||||||||||||||
Debt conversion shares issued | shares | 475,642 | |||||||||||||||
Benjamin Kaplan [Member] | ||||||||||||||||
Warrants exercise price | $ / shares | $ 0.01 | |||||||||||||||
Cancellation of warrants | shares | 3,358,498 | |||||||||||||||
General and administrative expenses | $ 720,695 | |||||||||||||||
Benjamin Kaplan [Member] | Executive Consulting Agreement [Member] | ||||||||||||||||
Warrants exercise price | $ / shares | $ 0.01 | |||||||||||||||
Term of notes | 24 months | |||||||||||||||
Related Party [Member] | ||||||||||||||||
Number of shares issued for services, shares | shares | 775,194 | |||||||||||||||
Two Convertible promissory Notes [Member] | ||||||||||||||||
Debt instrument, principal amount | 256,520 | |||||||||||||||
Debt original issue discount | $ 23,320 | |||||||||||||||
Aggregate of warrants | shares | 2,565,200 | |||||||||||||||
Warrants exercise price | $ / shares | $ 0.01 | |||||||||||||||
Term of notes | 18 months | |||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||
Convertible Promissory Note One [Member] | ||||||||||||||||
Debt instrument, principal amount | $ 178,189 | |||||||||||||||
Debt instrument, maturity date | Jul. 17, 2021 | |||||||||||||||
Convertible Promissory Note Two [Member] | ||||||||||||||||
Debt instrument, principal amount | $ 78,331 | |||||||||||||||
Debt instrument, maturity date | Jul. 29, 2021 | |||||||||||||||
Convertible Promissory Note Three [Member] | ||||||||||||||||
Debt instrument, principal amount | $ 11,000 | |||||||||||||||
Debt original issue discount | $ 1,000 | |||||||||||||||
Aggregate of warrants | shares | 110,000 | |||||||||||||||
Warrants exercise price | $ / shares | $ 0.01 | |||||||||||||||
Term of notes | 18 months | |||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||
Debt instrument, maturity date | May 11, 2022 | |||||||||||||||
Debt instrument conversion price per share | $ / shares | $ 0.01 | |||||||||||||||
Demand Non-Interest Secured Promissory Notes [Member] | ||||||||||||||||
Debt instrument, principal amount | $ 85,756 | |||||||||||||||
Debt original issue discount | $ 18,841 | |||||||||||||||
Demand Non-Interest Secured Promissory Notes [Member] | CAD [Member] | ||||||||||||||||
Debt instrument, principal amount | $ 125,000 | |||||||||||||||
Debt original issue discount | $ 25,000 | |||||||||||||||
Demand Non-Interest Unsecured Promissory Note [Member] | ||||||||||||||||
Debt instrument, principal amount | $ 98,351 | |||||||||||||||
Debt original issue discount | 23,663 | |||||||||||||||
Repayments to related party debt | $ 85,756 | |||||||||||||||
Demand Non-Interest Unsecured Promissory Note [Member] | Repayment of Debt [Member] | ||||||||||||||||
Repayments to related party debt | $ 95,351 | |||||||||||||||
Demand Non-Interest Unsecured Promissory Note [Member] | CAD [Member] | ||||||||||||||||
Debt instrument, principal amount | $ 131,683 | |||||||||||||||
Debt original issue discount | $ 31,683 | |||||||||||||||
2018 Converted Debt [Member] | Exchange Agreement [Member] | ||||||||||||||||
Debt instrument, principal amount | $ 3,145,777 | $ 3,145,777 | $ 3,145,777 | |||||||||||||
Debt conversion shares issued | shares | 20,350,573 | 20,350,573 | ||||||||||||||
Cancellation of warrants | shares | 560,461 | 560,461 | 560,461 |
Promissory and Convertible No_2
Promissory and Convertible Notes (Details Narrative) | May 24, 2019USD ($) | Feb. 27, 2019USD ($)shares | Feb. 27, 2019USD ($)shares | Dec. 31, 2020USD ($)$ / sharesshares | Dec. 31, 2019USD ($) | Jan. 28, 2019USD ($) | Jan. 21, 2019USD ($) | Jan. 21, 2019CAD ($) |
Debt principal amount | $ 2,845,414 | $ 2,845,414 | ||||||
Number of warrant issued | shares | 100,909 | |||||||
Debt discount | $ 200,313 | $ 200,313 | ||||||
Debt converted into shares | shares | 19,711,362 | |||||||
Amortization expenses | 804,356 | |||||||
Amortization of debt discount | 896,348 | |||||||
Number of warrants cancelled | shares | 2,250,000 | |||||||
CAD [Member] | ||||||||
Debt principal amount | $ 3,740,431 | 3,740,431 | ||||||
Convertible Promissory Note [Member] | ||||||||
Debt principal amount | 2,544,487 | |||||||
Original issue discount | $ 231,317 | |||||||
Number of warrant issued | shares | 2,544,870 | |||||||
Warrants exercise price | $ / shares | $ 0.01 | |||||||
Term of notes | 18 months | |||||||
Debt interest rate | 8.00% | |||||||
Debt maturity description | The notes mature beginning on July 10, 2021 thru June 28, 2022. | |||||||
Debt instrument conversion price per share | $ / shares | $ 0.01 | |||||||
Debt discount | $ 2,407,582 | |||||||
Debt converted into shares, value | $ 378,182 | |||||||
Debt converted into shares | shares | 37,818,154 | |||||||
Amortization expenses | $ 896,348 | |||||||
Amortization of debt discount | 804,356 | |||||||
Interest expenses on debt | 91,992 | |||||||
Convertible Promissory Note [Member] | Related Party [Member] | ||||||||
Debt principal amount | $ 267,520 | |||||||
Senior Secured Promissory Notes [Member] | ||||||||
Debt principal amount | $ 85,756 | $ 263,192 | ||||||
Original issue discount | 18,841 | |||||||
Repayments of debt | $ 85,756 | |||||||
Senior Secured Promissory Notes [Member] | CAD [Member] | ||||||||
Debt principal amount | 125,000 | $ 350,000 | ||||||
Original issue discount | $ 25,000 | |||||||
2018 Converted Debt [Member] | Exchange Agreement [Member] | ||||||||
Debt principal amount | $ 3,145,777 | $ 3,145,777 | ||||||
Number of warrant issued | shares | 560,461 | 560,461 | ||||||
Debt converted into shares, value | $ 3,145,777 | |||||||
Debt converted into shares | shares | 20,350,573 | 20,350,573 | ||||||
Number of warrants cancelled | shares | 560,461 |
Development Grant (Details Narr
Development Grant (Details Narrative) - Canada-Israel Research and Development Foundation [Member] | Jun. 07, 2013USD ($) | Dec. 31, 2020USD ($) | Jun. 07, 2013CAD ($) |
Grant repayable percentage | 2.50% | ||
Other income | $ 176,933 | ||
CAD [Member] | |||
Funds for development activities | $ 225,000 | ||
Maximum [Member] | CAD [Member] | |||
Funds for development activities | $ 300,000 |
Income Taxes (Details Narrative
Income Taxes (Details Narrative) | 12 Months Ended | |||
Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | Dec. 31, 2020CAD ($) | Dec. 31, 2019CAD ($) | |
Provision for income tax | ||||
Net operating loss, description | Carried forward over 20 years | |||
CAD [Member] | ||||
Net operating loss | $ 8,603,671 | $ 6,143,402 |
Income Taxes - Schedule of Defe
Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Income Tax Disclosure [Abstract] | ||
Deferred tax asset, beginning | $ 741,000 | $ 704,000 |
Increase in valuation reserve | 333,000 | 37,000 |
Deferred tax asset, ending | 1,074,000 | 741,000 |
Valuation Allowance | (1,074,000) | (741,000) |
Net Deferred tax assets |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) - USD ($) | Jan. 02, 2020 | Jun. 24, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Jun. 29, 2019 |
General and administration expenses | $ 2,046,573 | $ 411,019 | |||
Lease expenses | 2,500 | ||||
Office space and related expenses | $ 73,000 | 18,000 | |||
Benjamin Kaplan [Member] | |||||
Warrants exercise price | $ 0.01 | ||||
General and administration expenses | $ 720,695 | ||||
Accrued other payables | 91,000 | 18,000 | |||
Collaboration Agreement [Member] | |||||
Royalty payment | 10,000 | 5,000 | |||
Executive Consulting Agreement [Member] | |||||
General and administration expenses | 1,040,694 | $ 172,091 | |||
Executive Consulting Agreement [Member] | Benjamin Kaplan [Member] | |||||
Agreement term | 24 months | ||||
Warrants exercise price | $ 0.01 | ||||
Warrant expiry date | Apr. 16, 2022 | ||||
Raised consideration value of significant transaction | $ 500,000 | ||||
Owed share of common stock | 15,624,694 | ||||
Other payable and interest expenses | $ 1,874,963 | ||||
Executive Consulting Agreement [Member] | Benjamin Kaplan [Member] | Minimum [Member] | |||||
Payment for contingent consideration | 500,000 | ||||
Payment of consideration for rendered services | $ 1,000,000 | ||||
Consulting Agreement [Member] | |||||
Owed share of common stock | 876,225 | ||||
Consultant fee | $ 6,500 | ||||
Other payable and consulting expenses | $ 109,159 | ||||
Consulting Agreement [Member] | Common Stock [Member] | |||||
Consultant fee | 4,000 | ||||
Consulting Agreement [Member] | Cash [Member] | |||||
Consultant fee | $ 2,500 | ||||
Medical Advisory Board Agreements [Member] | |||||
General and administration expenses | 105,438 | ||||
Accrued other payables | 105,438 | ||||
Medical Advisory Board Agreements [Member] | Common Stock [Member] | |||||
Payment of consideration for rendered services | 155,000 | ||||
Medical Advisory Board Agreements [Member] | Cash [Member] | |||||
Payment of consideration for rendered services | $ 10,000 |
Stockholders' Equity (Deficit_2
Stockholders' Equity (Deficit) (Details Narrative) - USD ($) | Sep. 15, 2020 | Aug. 04, 2020 | Aug. 02, 2020 | Feb. 27, 2019 | Dec. 31, 2020 | Dec. 31, 2019 |
Stock issued | $ 26,250 | |||||
Shares issued upon exercise of warrants | 100,909 | |||||
Number of warrants exercised | 110,000 | |||||
Debt principal amount | $ 2,845,414 | |||||
Accrued interest | $ 300,362 | $ 53,929 | $ 51,075 | |||
Debt converted into shares | 19,711,362 | |||||
Stock based compensation expense | $ 50,000 | $ 61,224 | ||||
General and administrative expenses | $ 2,046,573 | $ 411,019 | ||||
Dividend rate | 0.00% | |||||
Risk-free interest rate | 0.44% | |||||
Expected volatility | 162.24% | |||||
Number of stock issued for services | 378,597 | 408,163 | ||||
Number of warrants cancelled | 2,250,000 | |||||
Anti-dilution provisions for common shares | 328,111 | |||||
Intrinsic value of warrants outstanding | $ 2,926,612 | |||||
Benjamin Kaplan [Member] | ||||||
Shares issued upon exercise of warrants | 3,358,498 | |||||
Warrants issued during period, value | $ 720,695 | |||||
General and administrative expenses | $ 720,695 | |||||
Warrants exercise price | $ 0.01 | |||||
Dividend rate | 0.00% | |||||
Benjamin Kaplan [Member] | Minimum [Member] | ||||||
Stock price | $ 0.37 | |||||
Risk-free interest rate | 0.13% | |||||
Expected volatility | 648.00% | |||||
Benjamin Kaplan [Member] | Maximum [Member] | ||||||
Stock price | $ 0.12 | |||||
Risk-free interest rate | 0.20% | |||||
Expected volatility | 570.00% | |||||
Member of Management [Member] | ||||||
Stock based compensation expense | $ 50,000 | |||||
Number of stock issued for services | 378,597 | |||||
CAD [Member] | ||||||
Debt principal amount | $ 3,740,431 | |||||
Accrued interest | $ 394,693 | |||||
Convertible Promissory Note [Member] | ||||||
Shares issued for conversion of convertible securities | 37,818,154 | |||||
Shares issued upon exercise of warrants | 2,544,870 | |||||
Debt principal amount | $ 2,544,487 | |||||
Debt converted into shares | 37,818,154 | |||||
Warrants exercise price | $ 0.01 | |||||
Psychedelitech, Inc. [Member] | ||||||
Number of shares purchased | 1,050,000 | |||||
Ownership percentage | 10.00% | |||||
Cost of investment | $ 26,250 | |||||
Bezalel Partners LLC [Member] | ||||||
Number of stock issued for services | 475,642 | |||||
Number of stock issued for services, value | $ 237,821 | |||||
KW Capital Partners Ltd [Member] | ||||||
Number of stock issued for services | 317,095 | |||||
Number of stock issued for services, value | $ 158,547 | |||||
Strategic Alliance Agreement [Member] | ||||||
Stock issued, shares | 1,050,000 | |||||
Stock issued | $ 26,250 | |||||
Asset Sale and Purchase Agreement [Member] | ||||||
Stock issued, shares | 353,622 | |||||
Stock issued | $ 40,000 | |||||
Finder's Fee Agreement [Member] | ||||||
Stock issued, shares | 1,250,000 | |||||
Stock issued | $ 46,875 | |||||
Compensation for services description | Total compensation for the consultant's efforts and services shall be a cash fee of 10% of the total principal amount of gross proceeds from any financing and 10% of the total shares of common stock purchased or convertible equivalent. | |||||
Stock based compensation expense | $ 63,500 |
Stockholders' Equity (Deficit_3
Stockholders' Equity (Deficit) - Schedule of Stock Option Activity (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Equity [Abstract] | ||
Shares outstanding, beginning balance | 86,251 | |
Shares outstanding, granted | ||
Shares outstanding, exercised | ||
Shares outstanding, canceled | (86,251) | |
Shares outstanding, ending balance | ||
Weighted- average exercise price, beginning balance | ||
Weighted- average exercise price, granted | ||
Weighted- average exercise price, exercised | ||
Weighted- average exercise price, canceled | ||
Weighted- average exercise price, ending balance | ||
Weighted average remaining contractual term (in years), beginning balance | 0 years | 5 years |
Weighted average remaining contractual term (in years), granted | 0 years | 0 years |
Weighted average remaining contractual term (in years), ending balance | 0 years | 0 years |
Aggregate intrinsic value, beginning balance | ||
Aggregate Intrinsic Value, ending balance |
Stockholders' Equity (Deficit_4
Stockholders' Equity (Deficit) - Schedule of Warrants Activity (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Equity [Abstract] | ||
Underlying shares, beginning balance | 561,461 | |
Underlying shares, Granted | 28,803,368 | |
Underlying shares, Exercised | (110,000) | |
Underlying shares, Forfeited | 561,461 | |
Underlying shares, ending balance | 28,693,368 | |
Weighted average exercise price, beginning balance | ||
Weighted average exercise price, granted | 0.01 | |
Weighted average exercise price, exercised | 0.01 | |
Weighted average exercise price, forfeited | ||
Weighted average exercise price, ending balance | $ 0.01 | |
Weighted average term (years), beginning balance | 0 years | 0 years |
Weighted average term (years), granted | 1 year 4 months 28 days | 0 years |
Weighted average term (years), ending balance | 1 year 1 month 13 days | 0 years |
Stockholders' Equity (Deficit_5
Stockholders' Equity (Deficit) - Schedule of Stock Option Valuation Model Assumptions (Details) | 12 Months Ended |
Dec. 31, 2020 | |
Equity [Abstract] | |
Expected term, in years | 2 years 9 months 29 days |
Expected volatility | 162.24% |
Risk-free interest rate | 0.44% |
Dividend yield | 0.00% |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) - USD ($) | Jan. 31, 2021 | Jan. 21, 2021 | Jan. 19, 2021 | Jan. 02, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Value of shares issued upon conversion | $ 378,182 | |||||
Value of shares purchase during the acquisition | 40,000 | |||||
Investments | $ 26,250 | |||||
Common Stock [Member] | ||||||
Number of shares issued upon conversion | 37,818,154 | |||||
Value of shares issued upon conversion | $ 378,182 | |||||
Number of shares purchase during acquisition | 353,622 | |||||
Value of shares purchase during the acquisition | $ 40,000 | |||||
Share issued | 1,050,000 | |||||
Asset Sale and Purchase Agreement [Member] | ||||||
Share issued | 353,622 | |||||
Subsequent Event [Member] | ||||||
Number of shares issued upon conversion | 15,649,446 | |||||
Value of shares issued upon conversion | $ 156,494 | |||||
Cashless exercise of warrants | 1,870,000 | |||||
Subsequent Event [Member] | Promissory Notes [Member] | ||||||
Proceeds from promissory note | $ 522,000 | |||||
Debt description | The notes carry an additional original issue discount payable of $52,750 representing interest as no other interest accrues on the notes unless there is an event of default, at which time interest will accrue at 22.0%, The notes mature eighteen months after the dates of issuance. The holder of the notes can exercise conversion at any time the note remains outstanding at a price of $0.01 per share. Upon the closing of a financing event of the Company, the notes will automatically convert at the conversion price of $0.01 per share. | |||||
Debt original issue discount | $ 52,750 | |||||
Debt instrument, interest rate | 22.00% | |||||
Debt, conversion price per share | $ 0.01 | |||||
Warrants exercise price | $ 0.01 | |||||
Warrant term | 2 years | |||||
Subsequent Event [Member] | Regulation A Offering [Member] | ||||||
Investments | $ 1,159,000 | |||||
Share issued | 16,557,142 | |||||
Subsequent Event [Member] | Common Stock [Member] | ||||||
Share issued | 1,746,084 | |||||
Subsequent Event [Member] | Medical Advisory Board Agreement [Member] | Common Stock [Member] | ||||||
Share issued | 281,000 | |||||
Subsequent Event [Member] | 20/20 Global [Member] | Common Stock [Member] | ||||||
Number of shares purchase during acquisition | 9,793,754 | |||||
Equity method investment, ownership percentage | 75.77% | |||||
Value of shares purchase during the acquisition | $ 350,000 | |||||
Subsequent Event [Member] | 20/20 Global [Member] | Mycotopioa Therapies, Inc. [Member] | Stock Purchase Agreement [Member] | ||||||
Purchase value of shares | $ 350,000 | |||||
Subsequent Event [Member] | CureDash, Inc [Member] | Asset Sale and Purchase Agreement [Member] | ||||||
Purchase price asset payable | $ 100,000 | |||||
Shares issued related to asset purchase | 353,622 | |||||
Cash paid related to asset purchase | $ 60,000 |